Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,139.56 +1,136.30 (+1.70%) CMC Crypto 200
1,380.37 +49.77 (+3.74%)
Alnylam Pharmaceuticals, Inc. (0HD2.L)
| Previous close | 241.25 |
| Open | 235.80 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 233.68 - 239.36 |
| 52-week range | 143.66 - 239.36 |
| Volume | |
| Avg. volume | 1,441 |
| Market cap | 26.844B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
CAMBRIDGE, Mass., July 18, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open.
- Business Wire
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
CAMBRIDGE, Mass., June 24, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
- Business Wire
Alnylam Issues 2023 Corporate Responsibility Report
CAMBRIDGE, Mass., May 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2023 Corporate Responsibility Report. The company continues to take meaningful steps across each of its six corporate responsibility pillars. This year’s edition expands data disclosures across each pillar and highlights examples of the company’s commitment to ensuring patient access, reducing health inequities, and being a responsible stewar
